Updates are available Correction dated 2022-12-21

Article History

Received: 17 December 2021

Accepted: 21 May 2022

First Online: 18 June 2022

Change Date: 21 December 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00455-022-10540-3

Declarations

:

: Dr. Kitagawa reports grants and personal fees from ASAHI KASEI PHARMA CORPORATION, grants and personal fees from TAIHO PHARMACEUTICAL CO., LTD, grants and personal fees from CHUGAI PHARMACEUTICAL CO., LTD., grants and personal fees from EA Pharma Co., Ltd., grants and personal fees from Yakult Honsha Co. Ltd., grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants from Takeda Pharmaceutical Co., Ltd., grants and personal fees from Otsuka Pharmaceutical Factory Inc., grants from KAKEN PHARMACEUTICAL CO.,LTD., grants and personal fees from Astellas Pharma Inc., grants from MEDICON INC., grants and personal fees from DAINIPPON SUMITOMO PHARMA Co., Ltd., grants and personal fees from Toyama Chemical Co., Ltd., grants from Kyouwa Hakkou Kirin Co., Ltd., grants and personal fees from ONO PHARMACEUTICAL CO., LTD., grants and personal fees from NIHON PHARMACEUTICAL CO., LTD., grants from TSUMURA & CO., grants from Nippon Covidien Inc., grants from Eisai Co., Ltd., grants from TEIJIN PHARMA LIMITED., personal fees from SHIONOGI & CO., LTD., personal fees from Bristol-Myers Squibb K.K., outside the submitted work. The other authors declare that they have no conflict of interest.

: This study was approved by the Keio University School of Medicine Ethics Committee and conducted following the principles of the Declaration of Helsinki.

: Informed consent was obtained through an opt-out consent process. The outline of the study was published on the institution’s public website, and the participants were guaranteed the right to refuse participation.

: Not applicable.